$MNOV
MEDICINOVA INC

2019 Q4 Form 10-K Financial Statement

#000156459020004605 Filed on February 13, 2020

View on sec.gov

Income Statement

Concept 2019 Q4 2019 2018
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $400.0K $7.950M $9.960M
YoY Change 42.86% -20.18% 13.18%
% of Gross Profit
Research & Development $1.830M $5.700M $5.300M
YoY Change 771.43% 7.55% 35.9%
% of Gross Profit
Depreciation & Amortization $0.00 $23.94K $25.88K
YoY Change -100.0% -7.48% -7.89%
% of Gross Profit
Operating Expenses $2.220M $14.03M $5.300M
YoY Change 351.22% 164.74% -59.32%
Operating Profit -$14.03M
YoY Change
Interest Expense $250.0K $1.150M $940.0K
YoY Change -13.79% 22.34% 315336.24%
% of Operating Profit
Other Income/Expense, Net $0.00 -$46.16K -$22.89K
YoY Change 101.64% -10.57%
Pretax Income -$1.970M -$12.93M -$14.69M
YoY Change 838.1% -11.99% 13.52%
Income Tax $10.00K $12.66K $10.00K
% Of Pretax Income
Net Earnings -$1.980M -$12.94M -$14.68M
YoY Change 851.92% -11.81% 31.46%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$45.26K -$299.8K -$357.0K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q4 2019 2018
SHORT-TERM ASSETS
Cash & Short-Term Investments $63.80M $63.80M $62.30M
YoY Change 2.41% 2.41% 122.5%
Cash & Equivalents $63.79M $63.80M $62.30M
Short-Term Investments
Other Short-Term Assets $500.0K $500.0K $400.0K
YoY Change 25.0% 25.0% 33.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $64.30M $64.30M $62.80M
YoY Change 2.46% 2.39% 121.91%
LONG-TERM ASSETS
Property, Plant & Equipment $40.55K $400.0K $100.0K
YoY Change -23.68% 300.0% 0.0%
Goodwill $9.600M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments $0.00
YoY Change -100.0%
Other Assets $459.8K $100.0K $0.00
YoY Change 4096.12%
Total Long-Term Assets $14.90M $14.90M $14.40M
YoY Change 3.02% 3.47% -4.64%
TOTAL ASSETS
Total Short-Term Assets $64.30M $64.30M $62.80M
Total Long-Term Assets $14.90M $14.90M $14.40M
Total Assets $79.21M $79.20M $77.20M
YoY Change 2.57% 2.59% 77.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $451.3K $500.0K $600.0K
YoY Change -26.82% -16.67% -60.0%
Accrued Expenses $1.800M $1.800M $1.600M
YoY Change 14.27% 12.5% 14.29%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.228M $2.200M $2.200M
YoY Change 1.66% 0.0% -24.14%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $186.4K $1.900M $1.700M
YoY Change 584.86% 11.76% 0.0%
Total Long-Term Liabilities $186.4K $1.900M $1.700M
YoY Change 584.86% 11.76% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.228M $2.200M $2.200M
Total Long-Term Liabilities $186.4K $1.900M $1.700M
Total Liabilities $4.311M $4.300M $4.100M
YoY Change 4.75% 4.88% -14.58%
SHAREHOLDERS EQUITY
Retained Earnings -$369.1M
YoY Change 3.63%
Common Stock $444.1M
YoY Change 3.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $74.89M $74.90M $73.10M
YoY Change
Total Liabilities & Shareholders Equity $79.21M $79.20M $77.20M
YoY Change 2.57% 2.59% 77.88%

Cashflow Statement

Concept 2019 Q4 2019 2018
OPERATING ACTIVITIES
Net Income -$1.980M -$12.94M -$14.68M
YoY Change 851.92% -11.81% 31.46%
Depreciation, Depletion And Amortization $0.00 $23.94K $25.88K
YoY Change -100.0% -7.48% -7.89%
Cash From Operating Activities -$2.400M -$9.125M -$9.114M
YoY Change 46.34% 0.12% 31.63%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $11.27K $10.20K
YoY Change 10.51%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $640.0K
YoY Change -100.0%
Cash From Investing Activities -$10.00K -$11.27K $626.3K
YoY Change -101.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.340M 10.62M 42.81M
YoY Change 119.74% -75.2% 296.49%
NET CHANGE
Cash From Operating Activities -2.400M -9.125M -9.114M
Cash From Investing Activities -10.00K -11.27K 626.3K
Cash From Financing Activities 3.340M 10.62M 42.81M
Net Change In Cash 930.0K 1.479M 34.32M
YoY Change -875.0% -95.69% 786.14%
FREE CASH FLOW
Cash From Operating Activities -$2.400M -$9.125M -$9.114M
Capital Expenditures -$10.00K $11.27K $10.20K
Free Cash Flow -$2.390M -$9.136M -$9.124M
YoY Change 45.73% 0.13% 31.78%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 dei Entity File Number
EntityFileNumber
001-33185
CY2019 dei Document Transition Report
DocumentTransitionReport
false
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0927979
CY2019 dei Entity Address Address Line1
EntityAddressAddressLine1
4275 Executive Square
CY2019 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
CY2019 dei Entity Address City Or Town
EntityAddressCityOrTown
La Jolla
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2019 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92037
CY2019 dei City Area Code
CityAreaCode
858
CY2019 dei Local Phone Number
LocalPhoneNumber
373-1500
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63792657
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
511916
CY2019Q4 us-gaap Assets Current
AssetsCurrent
64304573
CY2019Q4 us-gaap Goodwill
Goodwill
9600240
CY2019Q4 mnov In Process Research And Development
InProcessResearchAndDevelopment
4800000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
40550
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2228238
CY2019Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1694163
CY2019Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
201792
CY2018Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
201792
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12660
CY2019 dei Document Annual Report
DocumentAnnualReport
true
CY2019 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2019 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2019 us-gaap Operating Expenses
OperatingExpenses
14031077
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-46163
CY2019 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
27320
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
626324
CY2019 mnov Proceeds From Issuance Of Common Stock Exercise Of Common Stock Options And Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockExerciseOfCommonStockOptionsAndWarrantsNetOfIssuanceCosts
10588231
CY2018 mnov Proceeds From Issuance Of Common Stock Exercise Of Common Stock Options And Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockExerciseOfCommonStockOptionsAndWarrantsNetOfIssuanceCosts
42757772
CY2019 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
27320
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10615551
CY2019 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-53
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1479239
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
62313418
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6330305
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
38472971
CY2018 mnov Stock Issued During Period Value Under At The Market Equity Distribution And Sales Agreements
StockIssuedDuringPeriodValueUnderAtTheMarketEquityDistributionAndSalesAgreements
1515105
CY2018 mnov Stock Issued During Period Value Upon Exercise Of Warrants
StockIssuedDuringPeriodValueUponExerciseOfWarrants
2362500
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4112649
CY2019 mnov Stock Issued During Period Value Under At The Market Equity Distribution And Sales Agreements
StockIssuedDuringPeriodValueUnderAtTheMarketEquityDistributionAndSalesAgreements
6469510
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4118721
CY2019 us-gaap Profit Loss
ProfitLoss
-12941658
CY2018 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
19867
CY2019 mnov Increase Decrease In Receivables Prepaid Deferred Expense And Other Current And Long Term Assets
IncreaseDecreaseInReceivablesPrepaidDeferredExpenseAndOtherCurrentAndLongTermAssets
514021
CY2018 mnov Increase Decrease In Receivables Prepaid Deferred Expense And Other Current And Long Term Assets
IncreaseDecreaseInReceivablesPrepaidDeferredExpenseAndOtherCurrentAndLongTermAssets
111682
CY2018 us-gaap Proceeds From Divestiture Of Interest In Joint Venture
ProceedsFromDivestitureOfInterestInJointVenture
636524
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10200
CY2019 us-gaap Income Taxes Paid
IncomeTaxesPaid
11265
CY2018 us-gaap Income Taxes Paid
IncomeTaxesPaid
6005
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;). The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations and Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company maintains cash balances at various financial institutions and such balances commonly exceed the $250,000 amount insured by the Federal Deposit Insurance Corporation. The Company also maintains money market funds at various financial institutions which are not federally insured although are invested primarily in U.S. government securities. The Company has not experienced any losses in such accounts and management believes that the Company does not have significant credit risk with respect to such cash and cash equivalents.</p>
CY2019 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2019 us-gaap Number Of Reporting Units
NumberOfReportingUnits
1
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5700000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5300000
CY2019 mnov Patents Expense
PatentsExpense
300000
CY2018 mnov Patents Expense
PatentsExpense
300000
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6802093
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6609647
CY2019Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
16326
CY2018Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
16121
CY2019Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
236622
CY2018Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
235095
CY2019Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
285461
CY2018Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
285446
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
538409
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
536662
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
497859
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
483528
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
768498
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1137869
CY2019Q4 mnov Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
572880
CY2018Q4 mnov Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
226597
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
80827
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
18763
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
354707
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
191932
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
400000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
399347
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
229450
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
190340
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
433653
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
34306
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
226766
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
534605
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
243313
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
216768
CY2019Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
mnov:AccruedLiabilitiesAndOtherLiabilitiesCurrent
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
182579
CY2019Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesNoncurrent
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y9M21D
CY2019Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.088
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
182847
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
144234
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
149951
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1532
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1404
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
479968
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5514038
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1222000
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
125391
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
1000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6609647
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1337000
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1017854
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
126700
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6802093
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5600093
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.03
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.11
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.25
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
4.52
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.61
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.67
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.05
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
8.84
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.61
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.74
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
1200833
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
1230833
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
105000
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
1202000
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.04
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.76
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
4.07
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
5.39
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
2.65
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5200000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
788423
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y1M6D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y1M6D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
11800000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
23600000
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
11800000
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
22200000
CY2019 mnov Stock Issuance Limit Under Employee Stock Purchase Plan Description
StockIssuanceLimitUnderEmployeeStockPurchasePlanDescription
shares reserved automatically increase each year by a number equal to the lesser of: (i) 15,000 shares; (ii) 1% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year; or (iii) such lesser amount as determined by the Board
CY2019 mnov Employee Stock Purchase Plan Offering Period
EmployeeStockPurchasePlanOfferingPeriod
P6M
CY2019 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
3942
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.57
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4112649
CY2019Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
200000
CY2019 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P14D
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9289321
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-12952730
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-14689617
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
23732
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
19806
CY2019 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
12660
CY2018 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
5276
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
12660
CY2018 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
5276
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
64601000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
62025000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
176000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
286000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
8690000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
8434000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3120000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3922000
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
601000
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
580000
CY2018Q4 mnov Deferred Tax Assets Right Of Use Asset
DeferredTaxAssetsRightOfUseAsset
74000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
77262000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
75247000
CY2018Q4 mnov Deferred Tax Liabilities Right Of Use Liability
DeferredTaxLiabilitiesRightOfUseLiability
68000
CY2018Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
1343000
CY2017Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
1343000
CY2018Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1411000
CY2017Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1343000
CY2018Q4 mnov Deferred Tax Assets Liabilities Before Valuation Allowance
DeferredTaxAssetsLiabilitiesBeforeValuationAllowance
75851000
CY2017Q4 mnov Deferred Tax Assets Liabilities Before Valuation Allowance
DeferredTaxAssetsLiabilitiesBeforeValuationAllowance
73904000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
76053000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
74106000
CY2018Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
202000
CY2017Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
202000
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.032
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.064
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.020
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.015
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.150
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.272
CY2019 mnov Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.001
CY2018 mnov Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.001
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.111
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.017
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.001
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.001
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
78412
CY2018 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
76903

Files In Submission

Name View Source Status
0001564590-20-004605-index-headers.html Edgar Link pending
0001564590-20-004605-index.html Edgar Link pending
0001564590-20-004605.txt Edgar Link pending
0001564590-20-004605-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mnov-10k_20191231.htm Edgar Link pending
mnov-20191231.xml Edgar Link completed
mnov-20191231.xsd Edgar Link pending
mnov-20191231_cal.xml Edgar Link unprocessable
mnov-20191231_def.xml Edgar Link unprocessable
mnov-20191231_lab.xml Edgar Link unprocessable
mnov-20191231_pre.xml Edgar Link unprocessable
mnov-ex231_7.htm Edgar Link pending
mnov-ex311_6.htm Edgar Link pending
mnov-ex312_10.htm Edgar Link pending
mnov-ex321_8.htm Edgar Link pending
mnov-ex322_9.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending